NCT02109913 - Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane | Biotech Hunter

Enrollment

175

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions

Hormone Receptor Positive Malignant Neoplasm of BreastMetastatic Breast Cancer

Interventions

DRUG

Everolimus plus Exemestane

Everolimus 10mg, oral, daily; exemestane 25 mg, oral, daily. Number of Cycles: until progression or unacceptable toxicity develops. From all patients, 4 additional blood samples, 6ml each, will be collected and an optional tumor biopsy will be taken, if eligible.

Trial Locations (28)

1007 MB

VU University Medical Center, Amsterdam

Unknown

Flevoziekenhuis, Almere Stad

BovenIJ Ziekenhuis, Amsterdam

The Netherlands Cancer Institute, Amsterdam

Gelre, Apeldoorn

Rijnstate Ziekenhuis, Arnhem

Amphia Ziekenhuis, Breda

Reinier de Graaf Groep, Delft

Gemini, Den Helder

Deventer Ziekenhuis, Deventer

Maxima Medisch Centrum, Eindhoven

Groene Hart Ziekenhuis, Gouda

Tergooi ziekenhuizen, Hilversum

Spaarne Ziekenuis, Hoofddorp

MC Leeuwarden, Leeuwarden

LUMC, Leiden

Canisius Ziekenhuis, Nijmegen

Bravis, Roosendaal and Bergen Op Zoom

Erasmus University Medical Center, Rotterdam

Ikazia, Rotterdam

Vlietland, Schiedam

Orbis MC, Sittard

Haga, The Hague

MC Haaglanden, The Hague

Elisabeth - Tweesteden, Tilburg

UMC Utrecht, Utrecht

VieCuri, Venray

Isala, Zwolle